Duncan Jarvis

Helen, you talked to David Spiegelhalter about this.

So I've got a question about what this means for our understanding of things like case fatality rates.

Does this mean that the different data sources will come up with different things for that?

Or what do we understand there?

Maybe it's time we go back to the people we talked to in Iceland to see how their population testing is gone and if there is actually any results from that yet.

audited in the data again that we can't quite explain so there we go a huge amount of uncertainty still even though we've got some new data on mortality

That's it for this episode.

We will be back next week with more.

We are looking at guidelines and the ethics of that, which Helen's particularly interested in.

And we're going to pick up on waste in research that we touched on today.

So subscribe on Apple Podcasts or Spotify or wherever else you get your podcasts from so you don't miss out on that.

all of the bmj's stuff on covid19 is free to access at the moment go to bmj.com slash coronavirus where you can find all of that so uh until next week it's goodbye from me goodbye from me and goodbye from me take care

Welcome back to Talk Evidence, your now weekly look at the world of evidence and especially around coronavirus, COVID-19.

Last week we talked about pneumonia and testing and this week we've got even more for you.

As always we've got our starts and stops and we've got some information on treatment on chloroquine or hydroxychloroquine and maybe something on diagnostic and prognostic modelling and then lastly we are going to be talking about PPE again.

As always, we're joined by our two favourite EBM nerds.

I've got Helen MacDonald and Carl Hennigan here.

Helen, can I get you to introduce yourself?

And I realise I keep forgetting to introduce myself.

I'm Duncan Jarvis.